Email this article The blood-saving effect of vasopressinergic V1 receptor agonists in urologic oncology
- Authors: Pylaeva N.Y.1, Birkun A.A.1, Samarin S.A.1, Makarov A.A.2, Salakhov S.N.2, Bondarev A.A.2, Kazinina E.N.1
-
Affiliations:
- S.I. Georgievskiy Medical Academy, V. I. Vernadskiy Crimean Federal University
- V.M. Efetov Crimean Republican Oncology Clinical Dispensary
- Issue: Vol 13, No 3 (2017)
- Pages: 119-123
- Section: ANESTHETIC MAINTENANCE IN ONCOUROLOGY
- Published: 30.09.2017
- URL: https://oncourology.eco-vector.com/oncur/article/view/715
- DOI: https://doi.org/10.17650/1726-9776-2017-13-3-119-123
- ID: 715
Cite item
Full Text
Abstract
Objective: to investigate whether it is expedient to use the selective vasopressinergic V1 receptor agonist Remestyp® (terlipressin) to reduce the amount of blood loss and the duration of urologic cancer surgery.
Materials and methods. Remestyp® was used as a selective vasopressor. The fact that the drugs in this group can be used in cancer surgery is due to their ability to induce pronounced vasospasm of the microvasculature of the parenchymal organs, by considerably reducing blood flow in the latter, which, by taking into account the abundant vascularization of tumor tissue with numerous arteriovenous anastomoses, allows more optimal surgical conditions to be created. At the same time, it should be noted that selective vasopressors do not enhance blood cell aggregation, which is especially important for urologic cancer patients who are often at an increased thrombosis risk due to the presence of comorbidity, advanced age and surgical duration. The retrospective and prospective studies enrolled 54 patients operated on for urologic cancer in the period from 2014 to 2015.
Results. Analysis of the results of the studies showed that the use of the drug from the group of vasopressinergic V1 receptor agonists resulted in decreased intraoperative blood loss in patients and contributed to a shorter surgical treatment duration.
Conclusion. The findings suggest that it is expedient to use selective vasopressors for surgical treatment quality improvement in urologic oncology.
About the authors
N. Yu. Pylaeva
S.I. Georgievskiy Medical Academy, V. I. Vernadskiy Crimean Federal University
Author for correspondence.
Email: natalja.pylaewa@yandex.ua
4 academika Vernadskogo Prospect, Simferopol’ 295007, Republic of Crimea, Russia Russian Federation
A. A. Birkun
S.I. Georgievskiy Medical Academy, V. I. Vernadskiy Crimean Federal University4 academika Vernadskogo Prospect, Simferopol’ 295007, Republic of Crimea, Russia
S. A. Samarin
S.I. Georgievskiy Medical Academy, V. I. Vernadskiy Crimean Federal University4 academika Vernadskogo Prospect, Simferopol’ 295007, Republic of Crimea, Russia
A. A. Makarov
V.M. Efetov Crimean Republican Oncology Clinical Dispensary49a Bespalova St., Simferopol’ 295023, Republic of Crimea, Russia
Sh. N. Salakhov
V.M. Efetov Crimean Republican Oncology Clinical Dispensary49a Bespalova St., Simferopol’ 295023, Republic of Crimea, Russia
A. A. Bondarev
V.M. Efetov Crimean Republican Oncology Clinical Dispensary49a Bespalova St., Simferopol’ 295023, Republic of Crimea, Russia
E. N. Kazinina
S.I. Georgievskiy Medical Academy, V. I. Vernadskiy Crimean Federal University4 academika Vernadskogo Prospect, Simferopol’ 295007, Republic of Crimea, Russia
References
Supplementary files
